The central government
will scale up the use of Pentavalent vaccines in 11 more states in India
following demand from them, Health Minister Ghulam Nabi Azad told parliament
Tuesday.
In a written reply in the Rajya Sabha, the health minister
also said that there has been rise in the reported adverse events following
immunization (AEFI) cases all over the country, including eight states where
Pentavalent vaccine was introduced in phased manner.
'The increase in reporting is not found to be associated with
Pentavalent vaccine use,' he said.
'The government shall continue to use Pentavalent vaccine in
11 more states - Andhra Pradesh, Assam, Bihar, Chhattisgarh, Jharkhand, Madhya
Pradesh, Punjab, Rajasthan, West Bengal, Delhi and Uttarakhand,' Azad added.
He said these states have requested for the introduction of
Pentavalent vaccine in their state after successful introduction of the vaccine
in eight states.
The states where the vaccine is being used are Tamil Nadu,
Kerala, Goa, Jammu and Kashmir, Haryana, Gujarat, Karnataka and Puducherry.
Pentavalent vaccine is a conjugate vaccine which combines
antigens against five infections - diphtheria, pertussis and tetanus (DPT),
hepatitis B and Hib - in a shot.
The vaccine was rolled out as part of introducing a
vaccination against Haemophilus influenzae type B (Hib) infection - a major
cause of meningitis and pneumonia deaths in children - in the national
immunisation schedule for infants.
There have been some infant deaths in some states after
Pentavalent vaccines. The government after safety and efficacy study found the
vaccine to be safe.
Azad said the increase in reported adverse cases has been due
to strengthening of the monitoring system, revision of the guidelines,
dissemination of guidelines, constitution of district and state committees and
regular review of all theses cases by the National AEFI committee.
Pentavalent vaccine is a licensed vaccine, Azad said, adding
that any drugs including vaccines are licensed and cleared by Drug Controller
General of India after examining the safety and efficacy profile of the
product.
No comments:
Post a Comment